APO Research
Talk to an analyst

APO RESEARCH · REPORT

Short Acting Beta Agonists

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Short Acting Beta Agonists Industry Growth and Trends Forecast to 2032

20 December 202599 pages

Choose your research edition.

Industry ResearchShort Acting Beta Agonists Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Short Acting Beta Agonists Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Short Acting Beta Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Short Acting Beta Agonists Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Short Acting Beta Agonists Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Short Acting Beta Agonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Short Acting Beta Agonists include Teva, Johnson & Johnson, Merck, Roche, GSK, Bayer AG, Viatris and Cipla Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Short Acting Beta Agonists market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Short Acting Beta Agonists market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Short Acting Beta Agonists market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Short Acting Beta Agonists.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Short Acting Beta Agonists market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Short Acting Beta Agonists Market by Company

Teva

Johnson & Johnson

Merck

Roche

GSK

Bayer AG

Viatris

Cipla Limited

Short Acting Beta Agonists Segment by Type

Levalbuterol

Albuterol

Pirbuterol

Other

Short Acting Beta Agonists Segment by Application

COPD

Asthma

Other

Short Acting Beta Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short Acting Beta Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Short Acting Beta Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short Acting Beta Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Short Acting Beta Agonists manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Short Acting Beta Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Levalbuterol Table 2. Major Company of Albuterol Table 3. Major Company of Pirbuterol Table 4. Major Company of Other Table 5. Global Short Acting Beta Agonists Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Short Acting Beta Agonists Sales by Type (2021-2026) & (k units) Table 7. Global Short Acting Beta Agonists Sales Market Share in Volume by Type (2021-2026) Table 8. Global Short Acting Beta Agonists Sales by Type (2021-2026) & (US$ Million) Table 9. Global Short Acting Beta Agonists Sales Market Share in Value by Type (2021-2026) Table 10. Global Short Acting Beta Agonists Price by Type (2021-2026) & (US$/unit) Table 11. Global Short Acting Beta Agonists Sales by Type (2027-2032) & (k units) Table 12. Global Short Acting Beta Agonists Sales Market Share in Volume by Type (2027-2032) Table 13. Global Short Acting Beta Agonists Sales by Type (2027-2032) & (US$ Million) Table 14. Global Short Acting Beta Agonists Sales Market Share in Value by Type (2027-2032) Table 15. Global Short Acting Beta Agonists Price by Type (2027-2032) & (US$/unit) Table 16. North America Short Acting Beta Agonists Sales by Type (2021-2026) & (k units) Table 17. North America Short Acting Beta Agonists Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Short Acting Beta Agonists Sales by Type (2021-2026) & (k units) Table 19. Europe Short Acting Beta Agonists Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Short Acting Beta Agonists Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Short Acting Beta Agonists Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Short Acting Beta Agonists Sales by Type (2021-2026) & (k units) Table 23. Latin America Short Acting Beta Agonists Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Short Acting Beta Agonists Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Short Acting Beta Agonists Sales by Type (2021-2026) & (US$ Million) Table 26. Short Acting Beta Agonists Industry Trends Table 27. Short Acting Beta Agonists Industry Drivers Table 28. Short Acting Beta Agonists Industry Opportunities and Challenges Table 29. Short Acting Beta Agonists Industry Restraints Table 30. Global Short Acting Beta Agonists Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Short Acting Beta Agonists Revenue Market Share by Company (2021-2026) Table 32. Global Short Acting Beta Agonists Sales by Company (2021-2026) & (k units) Table 33. Global Short Acting Beta Agonists Sales Share by Company (2021-2026) Table 34. Global Short Acting Beta Agonists Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Short Acting Beta Agonists Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Short Acting Beta Agonists Major Company Production Sites and Headquarters Table 37. Global Short Acting Beta Agonists Company, Product Type & Application Table 38. Global Short Acting Beta Agonists Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Short Acting Beta Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Short Acting Beta Agonists Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Short Acting Beta Agonists Sales by Region (2021-2026) & (k units) Table 43. Global Short Acting Beta Agonists Sales Market Share in Volume by Region (2021-2026) Table 44. Global Short Acting Beta Agonists Sales by Region (2021-2026) & (US$ Million) Table 45. Global Short Acting Beta Agonists Sales Market Share in Value by Region (2021-2026) Table 46. Global Short Acting Beta Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Short Acting Beta Agonists Sales by Region (2027-2032) & (k units) Table 48. Global Short Acting Beta Agonists Sales Market Share in Volume by Region (2027-2032) Table 49. Global Short Acting Beta Agonists Sales by Region (2027-2032) & (US$ Million) Table 50. Global Short Acting Beta Agonists Sales Market Share in Value by Region (2027-2032) Table 51. Global Short Acting Beta Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Short Acting Beta Agonists Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Short Acting Beta Agonists Sales by Application (2021-2026) & (k units) Table 54. Global Short Acting Beta Agonists Sales Market Share in Volume by Application (2021-2026) Table 55. Global Short Acting Beta Agonists Sales by Application (2021-2026) & (US$ Million) Table 56. Global Short Acting Beta Agonists Sales Market Share in Value by Application (2021-2026) Table 57. Global Short Acting Beta Agonists Price by Application (2021-2026) & (US$/unit) Table 58. Global Short Acting Beta Agonists Sales by Application (2027-2032) & (k units) Table 59. Global Short Acting Beta Agonists Sales Market Share in Volume by Application (2027-2032) Table 60. Global Short Acting Beta Agonists Sales by Application (2027-2032) & (US$ Million) Table 61. Global Short Acting Beta Agonists Sales Market Share in Value by Application (2027-2032) Table 62. Global Short Acting Beta Agonists Price by Application (2027-2032) & (US$/unit) Table 63. North America Short Acting Beta Agonists Sales by Application (2021-2026) & (k units) Table 64. North America Short Acting Beta Agonists Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Short Acting Beta Agonists Sales by Application (2021-2026) & (k units) Table 66. Europe Short Acting Beta Agonists Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Short Acting Beta Agonists Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Short Acting Beta Agonists Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Short Acting Beta Agonists Sales by Application (2021-2026) & (k units) Table 70. Latin America Short Acting Beta Agonists Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Short Acting Beta Agonists Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Short Acting Beta Agonists Sales by Application (2021-2026) & (US$ Million) Table 73. Teva Company Information Table 74. Teva Business Overview Table 75. Teva Short Acting Beta Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Teva Short Acting Beta Agonists Product Portfolio Table 77. Teva Recent Development Table 78. Johnson & Johnson Company Information Table 79. Johnson & Johnson Business Overview Table 80. Johnson & Johnson Short Acting Beta Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Johnson & Johnson Short Acting Beta Agonists Product Portfolio Table 82. Johnson & Johnson Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck Short Acting Beta Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Merck Short Acting Beta Agonists Product Portfolio Table 87. Merck Recent Development Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche Short Acting Beta Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Roche Short Acting Beta Agonists Product Portfolio Table 92. Roche Recent Development Table 93. GSK Company Information Table 94. GSK Business Overview Table 95. GSK Short Acting Beta Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. GSK Short Acting Beta Agonists Product Portfolio Table 97. GSK Recent Development Table 98. Bayer AG Company Information Table 99. Bayer AG Business Overview Table 100. Bayer AG Short Acting Beta Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Bayer AG Short Acting Beta Agonists Product Portfolio Table 102. Bayer AG Recent Development Table 103. Viatris Company Information Table 104. Viatris Business Overview Table 105. Viatris Short Acting Beta Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Viatris Short Acting Beta Agonists Product Portfolio Table 107. Viatris Recent Development Table 108. Cipla Limited Company Information Table 109. Cipla Limited Business Overview Table 110. Cipla Limited Short Acting Beta Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Cipla Limited Short Acting Beta Agonists Product Portfolio Table 112. Cipla Limited Recent Development Table 113. North America Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 114. North America Short Acting Beta Agonists Sales by Country (2021-2026) & (k units) Table 115. North America Short Acting Beta Agonists Sales Market Share by Country (2021-2026) Table 116. North America Short Acting Beta Agonists Sales Forecast by Country (2027-2032) & (k units) Table 117. North America Short Acting Beta Agonists Sales Market Share Forecast by Country (2027-2032) Table 118. North America Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. North America Short Acting Beta Agonists Market Size by Country (2021-2026) & (US$ Million) Table 120. North America Short Acting Beta Agonists Market Share by Country (2021-2026) Table 121. North America Short Acting Beta Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. North America Short Acting Beta Agonists Market Share Forecast by Country (2027-2032) Table 123. Europe Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 124. Europe Short Acting Beta Agonists Sales by Country (2021-2026) & (k units) Table 125. Europe Short Acting Beta Agonists Sales Market Share by Country (2021-2026) Table 126. Europe Short Acting Beta Agonists Sales Forecast by Country (2027-2032) & (k units) Table 127. Europe Short Acting Beta Agonists Sales Market Share Forecast by Country (2027-2032) Table 128. Europe Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Europe Short Acting Beta Agonists Market Size by Country (2021-2026) & (US$ Million) Table 130. Europe Short Acting Beta Agonists Market Share by Country (2021-2026) Table 131. Europe Short Acting Beta Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Europe Short Acting Beta Agonists Market Share Forecast by Country (2027-2032) Table 133. Asia-Pacific Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 134. Asia-Pacific Short Acting Beta Agonists Sales by Country (2021-2026) & (k units) Table 135. Asia-Pacific Short Acting Beta Agonists Sales Market Share by Country (2021-2026) Table 136. Asia-Pacific Short Acting Beta Agonists Sales Forecast by Country (2027-2032) & (k units) Table 137. Asia-Pacific Short Acting Beta Agonists Sales Market Share Forecast by Country (2027-2032) Table 138. Asia-Pacific Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Asia-Pacific Short Acting Beta Agonists Market Size by Country (2021-2026) & (US$ Million) Table 140. Asia-Pacific Short Acting Beta Agonists Market Share by Country (2021-2026) Table 141. Asia-Pacific Short Acting Beta Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Asia-Pacific Short Acting Beta Agonists Market Share Forecast by Country (2027-2032) Table 143. Latin America Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 144. Latin America Short Acting Beta Agonists Sales by Country (2021-2026) & (k units) Table 145. Latin America Short Acting Beta Agonists Sales Market Share by Country (2021-2026) Table 146. Latin America Short Acting Beta Agonists Sales Forecast by Country (2027-2032) & (k units) Table 147. Latin America Short Acting Beta Agonists Sales Market Share Forecast by Country (2027-2032) Table 148. Latin America Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Latin America Short Acting Beta Agonists Market Size by Country (2021-2026) & (US$ Million) Table 150. Latin America Short Acting Beta Agonists Market Share by Country (2021-2026) Table 151. Latin America Short Acting Beta Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Latin America Short Acting Beta Agonists Market Share Forecast by Country (2027-2032) Table 153. Middle East and Africa Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 154. Middle East and Africa Short Acting Beta Agonists Sales by Country (2021-2026) & (k units) Table 155. Middle East and Africa Short Acting Beta Agonists Sales Market Share by Country (2021-2026) Table 156. Middle East and Africa Short Acting Beta Agonists Sales Forecast by Country (2027-2032) & (k units) Table 157. Middle East and Africa Short Acting Beta Agonists Sales Market Share Forecast by Country (2027-2032) Table 158. Middle East and Africa Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East and Africa Short Acting Beta Agonists Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East and Africa Short Acting Beta Agonists Market Share by Country (2021-2026) Table 161. Middle East and Africa Short Acting Beta Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East and Africa Short Acting Beta Agonists Market Share Forecast by Country (2027-2032) Table 163. Key Raw Materials Table 164. Raw Materials Key Suppliers Table 165. Short Acting Beta Agonists Distributors List Table 166. Short Acting Beta Agonists Customers List Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Short Acting Beta Agonists Image Figure 2. Global Short Acting Beta Agonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Short Acting Beta Agonists Market Size (2021-2032) & (US$ Million) Figure 4. Global Short Acting Beta Agonists Sales (2021-2032) & (k units) Figure 5. Levalbuterol Image Figure 6. Global Levalbuterol Sales YoY Growth (2021-2032) & (k units) Figure 7. Albuterol Image Figure 8. Global Albuterol Sales YoY Growth (2021-2032) & (k units) Figure 9. Pirbuterol Image Figure 10. Global Pirbuterol Sales YoY Growth (2021-2032) & (k units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Short Acting Beta Agonists Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Short Acting Beta Agonists Market Share by Type 2025 VS 2032 Figure 15. North America Short Acting Beta Agonists Sales Market Share in Volume by Type in 2025 Figure 16. North America Short Acting Beta Agonists Sales Market Share in Value by Type in 2025 Figure 17. Europe Short Acting Beta Agonists Sales Market Share in Volume by Type in 2025 Figure 18. Europe Short Acting Beta Agonists Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Short Acting Beta Agonists Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Short Acting Beta Agonists Sales Market Share in Value by Type in 2025 Figure 21. Latin America Short Acting Beta Agonists Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Short Acting Beta Agonists Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Short Acting Beta Agonists Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Short Acting Beta Agonists Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Short Acting Beta Agonists Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. COPD Image Figure 28. Global COPD Sales YoY Growth (2021-2032) & (k units) Figure 29. Asthma Image Figure 30. Global Asthma Sales YoY Growth (2021-2032) & (k units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Short Acting Beta Agonists Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Short Acting Beta Agonists Market Share by Application 2025 VS 2032 Figure 35. North America Short Acting Beta Agonists Sales Market Share in Volume by Application in 2025 Figure 36. North America Short Acting Beta Agonists Sales Market Share in Value by Application in 2025 Figure 37. Europe Short Acting Beta Agonists Sales Market Share in Volume by Application in 2025 Figure 38. Europe Short Acting Beta Agonists Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Short Acting Beta Agonists Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Short Acting Beta Agonists Sales Market Share in Value by Application in 2025 Figure 41. Latin America Short Acting Beta Agonists Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Short Acting Beta Agonists Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Short Acting Beta Agonists Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Short Acting Beta Agonists Sales Market Share in Value by Application in 2025 Figure 45. North America Short Acting Beta Agonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Short Acting Beta Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Short Acting Beta Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Short Acting Beta Agonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Short Acting Beta Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Short Acting Beta Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Short Acting Beta Agonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Short Acting Beta Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Short Acting Beta Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Short Acting Beta Agonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Short Acting Beta Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Short Acting Beta Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Short Acting Beta Agonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Short Acting Beta Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Short Acting Beta Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Short Acting Beta Agonists Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Short Acting Beta Agonists Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Levalbuterol
  • Albuterol
  • Pirbuterol
  • Other
Applications
  • COPD
  • Asthma
  • Other
Companies covered
  • Teva
  • Johnson & Johnson
  • Merck
  • Roche
  • GSK
  • Bayer AG
  • Viatris
  • Cipla Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Short Acting Beta Agonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Short Acting Beta Agonists Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Short Acting Beta Agonists Market by Type
  6. 1.3.1 Levalbuterol
  7. 1.3.2 Albuterol
  8. 1.3.3 Pirbuterol
  9. 1.3.4 Other
  10. 1.4 Global Short Acting Beta Agonists Market Size by Type
  11. 1.4.1 Global Short Acting Beta Agonists Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Short Acting Beta Agonists Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Short Acting Beta Agonists Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Short Acting Beta Agonists Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Short Acting Beta Agonists Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Short Acting Beta Agonists Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Short Acting Beta Agonists Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Short Acting Beta Agonists Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Short Acting Beta Agonists Industry Trends
  2. 2.2 Short Acting Beta Agonists Industry Drivers
  3. 2.3 Short Acting Beta Agonists Industry Opportunities and Challenges
  4. 2.4 Short Acting Beta Agonists Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Short Acting Beta Agonists Revenue (2021-2026)
  2. 3.2 Global Top Players by Short Acting Beta Agonists Sales (2021-2026)
  3. 3.3 Global Top Players by Short Acting Beta Agonists Price (2021-2026)
  4. 3.4 Global Short Acting Beta Agonists Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Short Acting Beta Agonists Major Company Production Sites & Headquarters
  6. 3.6 Global Short Acting Beta Agonists Company, Product Type & Application
  7. 3.7 Global Short Acting Beta Agonists Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Short Acting Beta Agonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Short Acting Beta Agonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Short Acting Beta Agonists Tier 1, Tier 2, and Tier 3
4 Short Acting Beta Agonists Regional Status and Outlook
  1. 4.1 Global Short Acting Beta Agonists Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Short Acting Beta Agonists Historic Market Size by Region
  3. 4.2.1 Global Short Acting Beta Agonists Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Short Acting Beta Agonists Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Short Acting Beta Agonists Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Short Acting Beta Agonists Forecasted Market Size by Region
  7. 4.3.1 Global Short Acting Beta Agonists Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Short Acting Beta Agonists Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Short Acting Beta Agonists Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Short Acting Beta Agonists by Application
  1. 5.1 Short Acting Beta Agonists Market by Application
  2. 5.1.1 COPD
  3. 5.1.2 Asthma
  4. 5.1.3 Other
  5. 5.2 Global Short Acting Beta Agonists Market Size by Application
  6. 5.2.1 Global Short Acting Beta Agonists Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Short Acting Beta Agonists Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Short Acting Beta Agonists Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Short Acting Beta Agonists Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Short Acting Beta Agonists Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Short Acting Beta Agonists Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Short Acting Beta Agonists Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Short Acting Beta Agonists Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva
  2. 6.1.1 Teva Company Information
  3. 6.1.2 Teva Business Overview
  4. 6.1.3 Teva Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Short Acting Beta Agonists Product Portfolio
  6. 6.1.5 Teva Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Short Acting Beta Agonists Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Short Acting Beta Agonists Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Roche
  20. 6.4.1 Roche Company Information
  21. 6.4.2 Roche Business Overview
  22. 6.4.3 Roche Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Roche Short Acting Beta Agonists Product Portfolio
  24. 6.4.5 Roche Recent Developments
  25. 6.5 GSK
  26. 6.5.1 GSK Company Information
  27. 6.5.2 GSK Business Overview
  28. 6.5.3 GSK Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 GSK Short Acting Beta Agonists Product Portfolio
  30. 6.5.5 GSK Recent Developments
  31. 6.6 Bayer AG
  32. 6.6.1 Bayer AG Company Information
  33. 6.6.2 Bayer AG Business Overview
  34. 6.6.3 Bayer AG Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Bayer AG Short Acting Beta Agonists Product Portfolio
  36. 6.6.5 Bayer AG Recent Developments
  37. 6.7 Viatris
  38. 6.7.1 Viatris Company Information
  39. 6.7.2 Viatris Business Overview
  40. 6.7.3 Viatris Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Viatris Short Acting Beta Agonists Product Portfolio
  42. 6.7.5 Viatris Recent Developments
  43. 6.8 Cipla Limited
  44. 6.8.1 Cipla Limited Company Information
  45. 6.8.2 Cipla Limited Business Overview
  46. 6.8.3 Cipla Limited Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Cipla Limited Short Acting Beta Agonists Product Portfolio
  48. 6.8.5 Cipla Limited Recent Developments
7 North America by Country
  1. 7.1 North America Short Acting Beta Agonists Sales by Country
  2. 7.1.1 North America Short Acting Beta Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Short Acting Beta Agonists Sales by Country (2021-2026)
  4. 7.1.3 North America Short Acting Beta Agonists Sales Forecast by Country (2027-2032)
  5. 7.2 North America Short Acting Beta Agonists Market Size by Country
  6. 7.2.1 North America Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Short Acting Beta Agonists Market Size by Country (2021-2026)
  8. 7.2.3 North America Short Acting Beta Agonists Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Short Acting Beta Agonists Sales by Country
  2. 8.1.1 Europe Short Acting Beta Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Short Acting Beta Agonists Sales by Country (2021-2026)
  4. 8.1.3 Europe Short Acting Beta Agonists Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Short Acting Beta Agonists Market Size by Country
  6. 8.2.1 Europe Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Short Acting Beta Agonists Market Size by Country (2021-2026)
  8. 8.2.3 Europe Short Acting Beta Agonists Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Short Acting Beta Agonists Sales by Country
  2. 9.1.1 Asia-Pacific Short Acting Beta Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Short Acting Beta Agonists Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Short Acting Beta Agonists Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Short Acting Beta Agonists Market Size by Country
  6. 9.2.1 Asia-Pacific Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Short Acting Beta Agonists Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Short Acting Beta Agonists Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Short Acting Beta Agonists Sales by Country
  2. 10.1.1 South America Short Acting Beta Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Short Acting Beta Agonists Sales by Country (2021-2026)
  4. 10.1.3 South America Short Acting Beta Agonists Sales Forecast by Country (2027-2032)
  5. 10.2 South America Short Acting Beta Agonists Market Size by Country
  6. 10.2.1 South America Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Short Acting Beta Agonists Market Size by Country (2021-2026)
  8. 10.2.3 South America Short Acting Beta Agonists Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Short Acting Beta Agonists Sales by Country
  2. 11.1.1 Middle East and Africa Short Acting Beta Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Short Acting Beta Agonists Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Short Acting Beta Agonists Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Short Acting Beta Agonists Market Size by Country
  6. 11.2.1 Middle East and Africa Short Acting Beta Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Short Acting Beta Agonists Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Short Acting Beta Agonists Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Short Acting Beta Agonists Value Chain Analysis
  2. 12.1.1 Short Acting Beta Agonists Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Short Acting Beta Agonists Production Mode & Process
  7. 12.2 Short Acting Beta Agonists Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Short Acting Beta Agonists Distributors
  10. 12.2.3 Short Acting Beta Agonists Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst